Bando, Hiroshi Kanaiso Hospital|Tokushima University|Japan Low Carbohydrate Diet Promotion Association KAKEN Search Researchers
Yamashita, Hisako Kanaiso Hospital
Kato, Yoshinobu Kanaiso Hospital
Ogura, Katsunori Kanaiso Hospital
Kato, Yoshikane Kanaiso Hospital
Kanazawa, Setsuko Kanaiso Hospital
Type 2 diabetes
Background: Obesity and Type 2 Diabetes (T2D) are crucial problems worldwide. Oral semaglutide (Rybelsus) was introduced to medical practice for Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA). Case presentation: The patient is 24-year-old female with obesity (BMI 39.3 kg/m2), T2D and fatty liver. Results: She started and increased Rybelsus from 3mg, 7mg to 14mg/day each 4 weeks. She showed significant efficacy for 4 months as HbA1c 6.3% to 5.6% and weight 107kg to 103kg, without Gastrointestinal Adverse Events (GIAEs). Discussion: Rybelsus is provided just after waking up, and kept >30 min fasting period. Longer fasting time may contribute current effect.
Journal of Obesity and Diabetes
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
|DOI (Published Version)|
|URL ( Publisher's Version )|
jod_5_1_11.pdf 968 KB